Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant 
and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily

Read more at globenewswire.com